Effects of aging and rifampicin pretreatment on the pharmacokinetics of human cytochrome P450 probes caffeine, warfarin, omeprazole, metoprolol and midazolam in common marmosets genotyped for cytochrome P450 2C19

References

• Birkett DJ, Andersson T, Miners JO. (1996). Assays of omeprazole metabolism as a substrate probe for human CYP isoforms. Methods Enzymol 272:132–9
   PubMed Web of Science ®Google Scholar
• Combalbert J, Fabre I, Fabre G, et al. (1989). Metabolism of cyclosporin A IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 17:197–207
   PubMed Web of Science ®Google Scholar
• Corsonello A, Pedone C, Incalzi RA. (2010). Age-related pharmacokinetic and pharmacodynamic changes and related risk of adverse drug reactions. Curr Med Chem 17:571–84
   PubMed Web of Science ®Google Scholar
• Gorski JC, Vannaprasaht S, Hamman MA, et al. (2003). The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275–87
   PubMed Web of Science ®Google Scholar
• Ishizawa Y, Yasui-Furukori N, Takahata T, et al. (2005). The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44:1179–89
   PubMed Web of Science ®Google Scholar
• Jensen BP, Chin PK, Roberts RL, Begg EJ. (2012). Influence of adult age on the total and free clearance and protein binding of (R)- and (S)-warfarin. Br J Clin Pharmacol 74:797–805
   PubMed Web of Science ®Google Scholar
• Klotz U. (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 41:67–76
   PubMed Web of Science ®Google Scholar
• Koyanagi T, Nakanishi Y, Murayama N, et al. (2015). Age-related changes of hepatic clearances of cytochrome P450 probes, midazolam and R-/S-warfarin in combination with caffeine, omeprazole, and metoprolol in cynomolgus monkeys using in vitro-in vivo correlation. Xenobiotica 45:312–21
   PubMed Web of Science ®Google Scholar
• Koyanagi T, Yamaura K, Yano K, et al. (2014). Age-related pharmacokinetic changes of acetaminophen, antipyrine, diazepam, diphenhydramine, and ofloxacin in male cynomolgus monkeys and beagle dogs. Xenobiotica 44:893–901
   PubMed Web of Science ®Google Scholar
• Larsson M, Landahl S, Lundborg P, Regardh CG. (1984). Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment. Eur J Clin Pharmacol 27:217–22
   PubMed Web of Science ®Google Scholar
• McLachlan AJ, Pont LG. (2012). Drug metabolism in older people – a key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci 67:175–80
   PubMed Web of Science ®Google Scholar
• Obach RS, Lombardo F, Waters NJ. (2008). Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos 36:1385–405
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Yoshikawa T, Kozakai K, et al. (2010). Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab Dispos 38:1806–13
   PubMed Web of Science ®Google Scholar
• Parkinson A, Mudra DR, Johnson C, et al. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193–209
   PubMed Web of Science ®Google Scholar
• Qato DM, Alexander GC, Conti RM, et al. (2008). Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 300:2867–78
   PubMed Web of Science ®Google Scholar
• Shida S, Utoh M, Murayama N, et al. (2015). Human plasma concentrations of cytochrome P450 probes extrapolated from pharmacokinetics in cynomolgus monkeys using physiologically based pharmacokinetic modeling. Xenobiotica 45:881–6
   PubMed Web of Science ®Google Scholar
• Shida S, Yamazaki H. (2016). Human plasma concentrations of five cytochrome P450 probes extrapolated from pharmacokinetics in dogs and minipigs using physiologically based pharmacokinetic modeling. Xenobiotica 46:759–64
   PubMed Web of Science ®Google Scholar
• Turpault S, Brian W, Van Horn R, et al. (2009). Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68:928–35
   PubMed Web of Science ®Google Scholar
• Uehara S, Inoue T, Utoh M, et al. (2016a). Simultaneous pharmacokinetics evaluation of human cytochrome P450 probes, caffeine, warfarin, omeprazole, metoprolol, and midazolam, in common marmosets (Callithrix jacchus). Xenobiotica 46:163–8
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al. (2016b). Individual differences in metabolic clearance of S-warfarin efficiently mediated by polymorphic marmoset cytochrome P450 2C19 in livers. Drug Metab Dispos 44:911–5
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue T, et al. (2016c). Caffeine 7-N-demethylation and C-8-oxidation mediated by liver microsomal cytochrome P450 enzymes in common marmosets. Xenobiotica 46:573–8
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Inoue S, et al. (2015). Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab Dispos 43:1408–16
   PubMed Web of Science ®Google Scholar
• Uehara S, Ishii S, Uno Y, et al. (2017a). Regio- and stereo-selective oxidation of a cardiovascular drug metoprolol mediated by cytochrome P450 2D and 3A enzymes in marmoset livers. Drug Metab Dispos 45:896–9
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Nakanishi K, et al. (2017b). Marmoset cytochrome P450 3A4 orthologue expressed in liver and small intestine tissues efficiently metabolizes midazolam, alprazolam, nifedipine, and testosterone. Drug Metab Dispos 45:457–67
   PubMed Web of Science ®Google Scholar
• Uehara S, Uno Y, Suzuki T, et al. (2017c). Strong induction of cytochrome P450 1A/3A, but not P450 2B, in cultured hepatocytes from common marmosets and cynomolgus monkeys by typical human P450 inducing agents. Drug Metab Lett 10:244–53
   PubMedGoogle Scholar
• Uno Y, Uehara S, Yamazaki H. (2016). Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol 121:1–7
   PubMed Web of Science ®Google Scholar
• Utoh M, Kusama T, Miura T, et al. (2017). R-Warfarin clearances from plasma associated with polymorphic cytochrome P450 2C19 and simulated by individual physiologically based pharmacokinetic models for 11 cynomolgus monkeys. Xenobiotica. [Epub ahead of print]. doi: 10.1080/00498254.2017.1288945
   Web of Science ®Google Scholar
• Utoh M, Suemizu H, Mitsui M, et al. (2016). Human plasma concentrations of cytochrome P450 probe cocktails extrapolated from pharmacokinetics in mice transplanted with human hepatocytes and from pharmacokinetics in common marmosets using physiologically based pharmacokinetic modeling. Xenobiotica 46:1049–55
   PubMed Web of Science ®Google Scholar
• Utoh M, Yoshikawa T, Hayashi Y, et al. (2015). Slow R-warfarin 7-hydroxylation mediated by P450 2C19 genetic variants in cynomolgus monkeys in vivo. Biochem Pharmacol 95:110–4
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, et al. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434–42
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Suemizu H, Mitsui M, et al. (2016). Combining chimeric mice with humanized liver, mass spectrometry, and physiologically-based pharmacokinetic modeling in toxicology. Chem Res Toxicol 29:1903–11
   PubMed Web of Science ®Google Scholar